Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07000877
PHASE4

Nasal Decongestant to Reduce Perioperative Adverse Events in Children With Upper Respiratory Track Infections Having Anesthesia.

Sponsor: Telethon Kids Institute

View on ClinicalTrials.gov

Summary

The goal of this multicentre, double-blind, randomised controlled trial study is to learn if the use of a nasal spray to open the nasal passages and increase airflow before surgery can reduce the occurrence of perioperative respiratory adverse events in children with upper respiratory tract infection who are undergoing anesthesia. The main questions it aims to answer are: * Does use of a nasal decongestant (Oxymetazoline 0.05%) reduce perioperative respiratory adverse events during emergence (when waking up from anesthesia) or in the post-anesthesia care unit in children. * Is it easy and acceptable to doctors, children and parents to use the nasal decongestant treatment? Researchers will compare the nasal decongestant to a placebo (a look-alike substance that contains no drug) to see if it works to reduce perioperative respiratory adverse effects. Participants will: * Take a nasal decongestant or a placebo prior to surgery (just before anaesthesia is given) * Be monitored during and after surgery in the post-anaesthesia care unit for any perioperative respiratory adverse events. * Be asked about how acceptable they found the treatment.

Official title: Nasal Decongestant Administration to Reduce Perioperative Adverse Events in Children With Upper Respiratory Track Infections Having General Anesthesia - a Low Risk Intervention. (NARWHAL)

Key Details

Gender

All

Age Range

1 Year - 8 Years

Study Type

INTERVENTIONAL

Enrollment

200

Start Date

2025-06-25

Completion Date

2028-05-30

Last Updated

2025-11-19

Healthy Volunteers

No

Interventions

DRUG

Decongestant nasal spray (oxymetazoline hydrochloride (0.05%))

Decongestant nasal spray containing active ingredient.

DRUG

PLACEBO: 2.5mL of normal saline 0.9% and benzalkonium chloride 0.02%

Control nasal spray containing no active ingredient.

Locations (1)

Perth Children's Hospital

Perth, We, Australia